Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Trial Profile

A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Setmelanotide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Rhythm
  • Most Recent Events

    • 04 Jan 2019 According to a Rhythm Pharmaceuticals media release, the company expects to submit an NDA filing for Pro-opiomelanocortin (POMC) deficiency obesity to the U.S. Food and Drug Administration (FDA) in late 2019 or early 2020.
    • 14 Jun 2018 According to a Rhythm Pharmaceuticals media release, the company expects to report initial data from this trial in the third quarter of 2019.
    • 14 Jun 2018 According to a Rhythm Pharmaceuticals media release, enrollment of the pivotal cohort of 10 patients has been completed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top